How Progyny’s Revenue Beat but EPS Miss and Softer Outlook May Impact Progyny (PGNY) Investors

• Progyny recently reported quarterly revenue of US$318.4 million, up 6.7% year on year and ahead of analyst expectations, while also announcing a settlement of a stockholder derivative action over historical non‑employee director compensation.
• Despite record full-year revenue, Adjusted EBITDA, and operating cash flow, investor focus has shifted to the sizable miss on full-year EPS and weaker-than-expected guidance for the coming quarter.
• Next, we’ll examine how this revenue beat but weaker earnings and guidance might reshape Progyny’s investment narrative built on resilient employer demand.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Progyny Investment Narrative Recap

To own Progyny, you need to believe that employer demand for fertility and family-building benefits will stay resilient enough to support steady revenue and earnings growth. The latest quarter delivered a revenue beat and record full-year figures, but the EPS miss, weaker guidance, and 21% share price drop refocus attention on execution risk and profitability, rather than changing the core demand story. The derivative action settlement around director pay looks immaterial to the near term business outlook.

The most relevant recent update is Progyny’s February earnings release and 2026 guidance, which set the bar for how investors judge the latest quarter’s shortfall. With Q1 2026 revenue guided to US$319.0 million to US$332.0 million and full year 2026 to US$1,355 million to US$1,405 million, the key question is whether the company can convert resilient top-line demand into consistent EPS growth without letting costs creep ahead of revenue.

Yet beneath the strong revenue print, there is a risk investors should be aware of if employer benefit budgets start to...

Read the full narrative on Progyny (it's free!)

Progyny's narrative projects $1.6 billion revenue and $112.9 million earnings by 2028.

Uncover how Progyny's forecasts yield a $30.91 fair value, a 73% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Progyny to reach about US$1.8 billion of revenue and US$151.3 million of earnings by 2028, yet the latest revenue beat and EPS miss could push both that bullish view and the risk of employer benefit cuts in very different directions, so it is worth seeing how your own expectations compare.

Explore 4 other fair value estimates on Progyny - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Progyny research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Progyny research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Progyny's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com